ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Shattuck Labs Inc

Shattuck Labs Inc (STTK)

4.64
-0.10
(-2.11%)
Closed July 18 4:00PM
4.64
0.00
( 0.00% )
Pre Market: 6:28AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
4.64
Bid
4.71
Ask
4.80
Volume
8
0.00 Day's Range 0.00
1.3301 52 Week Range 11.76
Market Cap
Previous Close
4.64
Open
-
Last Trade
7
@
4.87
Last Trade Time
06:28:20
Financial Volume
-
VWAP
-
Average Volume (3m)
388,943
Shares Outstanding
47,550,872
Dividend Yield
-
PE Ratio
-2.53
Earnings Per Share (EPS)
-1.84
Revenue
1.66M
Net Profit
-87.3M

About Shattuck Labs Inc

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restor... Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
1970
Shattuck Labs Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker STTK. The last closing price for Shattuck Labs was $4.64. Over the last year, Shattuck Labs shares have traded in a share price range of $ 1.3301 to $ 11.76.

Shattuck Labs currently has 47,550,872 shares outstanding. The market capitalization of Shattuck Labs is $220.64 million. Shattuck Labs has a price to earnings ratio (PE ratio) of -2.53.

STTK Latest News

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

AUSTIN, TX & DURHAM, NC, July 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional...

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuke

– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median...

Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

AUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional...

Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Mye

- Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck...

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the Eu

– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.5714.00491400494.074.993.886266784.63700803CS
40.4611.0047846894.184.993.3454782504.12024492CS
12-5.18-52.7494908359.8211.763.3453889436.46726908CS
26-3.86-45.41176470598.511.763.3453508047.8768303CS
521.8968.72727272732.7511.761.33015871046.32004846CS
156-17.95-79.459938025722.5924.271.33012934386.91194483CS
260-13.97-75.067168189118.6160.51621.330127318910.6868984CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HUBCWHub Cyber Security Ltd
$ 0.0345
(94.92%)
62
SERVServe Robotics Inc
$ 4.72
(79.47%)
4.26M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.3334
(35.53%)
6.66M
GNLXGenelux Corporation
$ 2.90
(26.09%)
2
CXAICXApp Inc
$ 2.80
(25.56%)
647
KITTNauticus Robotics Inc
$ 0.101
(-21.64%)
984.44k
SPWRSunPower Corporation
$ 1.23
(-18.54%)
661.45k
MTEMMolecular Templates Inc
$ 1.21
(-15.38%)
1
AZA2Z Smart Technologies Corporation
$ 0.7623
(-14.33%)
173
GDTCCytoMed Therapeutics Ltd
$ 1.97
(-13.98%)
246
SXTP60 Degrees Pharmaceuticals Inc
$ 0.3334
(35.53%)
6.66M
SGDSafe and Green Development Corporation
$ 0.43
(16.28%)
5.98M
SERVServe Robotics Inc
$ 4.72
(79.47%)
4.26M
SQQQProShares UltraPro Short QQQ
$ 8.22
(-0.12%)
3.24M
MAXNMaxeon Solar Technologies Ltd
$ 0.2283
(-5.03%)
2.49M

STTK Discussion

View Posts
PonkenPlonken PonkenPlonken 2 months ago
absolutely revolutionary data in HR MDS... compare to SOC!!! HMAs show a ORR 30%, CR 10-20%
(also beats venetoclax + HMA in TP53m AML)

Observed 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete response (CR)/marrow complete response (mCR) rate of 64% –

– Observed 27% initial CR/complete response with incomplete hematologic recovery (CRi) in frontline TP53m AML patients, and 5/11 evaluable patients achieved stable disease with decreasing blast counts and peripheral blood count improvement, these patients continue on treatment
👍️0
Monksdream Monksdream 3 months ago
STTK new 52 week high
👍️0
Monksdream Monksdream 6 months ago
STTK new 52 week high
👍️0
Monksdream Monksdream 6 months ago
STTK new 52 week low
👍️0
tbonaces80 tbonaces80 7 months ago
Takeda gonna tender on next trial fast track
👍️0
tbonaces80 tbonaces80 7 months ago
load it-going to 10+
👍️0
subslover subslover 7 months ago
No fooling? So you say a 1.75% profit for a two-hour trade is a bad trade?
👍️0
tbonaces80 tbonaces80 7 months ago
Bad trade
👍️0
subslover subslover 7 months ago
Ok. I got out of this POS this morning at $5.00, got lucky is all
👍️0
TheFinalCD TheFinalCD 7 months ago
@ 4.29 I was just looking for a move under $4 and it did

small gain, but I didnt know how many borrows I could get if it went against me

sometimes I go short, and get upside down and cant average up, because broker all of a sudden has NO available shares to short= your stuck

so thats why I dont short much
👍️0
subslover subslover 7 months ago
What price did you short?tia
👍️0
TheFinalCD TheFinalCD 7 months ago
I shorted it... Its just Phase 1

AI bot hyper extended the POP

I used to chase these Pase 1 rallys, lost lots of money doing so

some of my biggest losses ever

Phase 1 Gap & Traps
👍️0
subslover subslover 7 months ago
Did you see this open? $7.28! then immediately dropped down to $2.50 omg. I'm in at $3.00 just hoping for the best. Worth a shot
👍️0
TheFinalCD TheFinalCD 7 months ago
$STTK KEEP THIS ON WATCH! pic.twitter.com/6owPN2LcXn— Tiger Line Trading (@TigerLineTrades) December 13, 2023
👍️0
subslover subslover 7 months ago
$TSOI's new Introducing the ALScell™, also known as the JadiCell™ – Now, these ALScells are not your run-of-the-mill mesenchymal stem cells; they're basically the overachievers of the cellular world. These ALScells have it all – enhanced growth factor production, like they've been hitting the gym and drinking protein shakes on a regular basis. They can secrete exosomes , outshining their stem cell peers who are still trying to figure out how to tie their cellular shoelaces.

But wait, there's more! These ALScells are not just content with being academically gifted; they've got some serious street smarts too. Superior angiogenic and neurogenic abilities mean they're like the cool kids who not only excel in science class but also throw legendary parties in the cellular neighborhood.

And guess what? Exosomes are not just a fancy word; they're the VIP pass to the cure of many cancers. It's like the ALScells are hosting the party, and exosomes are the invitations that cancer cells can't resist.

So, say hello to the ALScell™ – the cellular superhero ready to save the day, one enhanced growth factor at a time, and unlocking cures like a boss!
Bullish
BULLISH
👍️0
Awl416 Awl416 7 months ago
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Pati
👍️0
Monksdream Monksdream 10 months ago
STTK under $2
👍️0

Your Recent History

Delayed Upgrade Clock